Unbound MEDLINE

Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.

Abstract

New-generation antidepressants are a heterogeneous class of drugs used in the treatment of depression and related disorders. This review deals with the first new-generation antidepressant class to enter the pharmaceutical market, i.e., selective serotonin reuptake inhibitors (SSRIs), which are still the most prescribed and widely used ones. Their common characteristics are the comparable clinical efficacy, good tolerability and relative safety in comparison to "first generation antidepressants", i.e. classic tricyclic antidepressants and monoamine oxidase inhibitors. This class of drugs includes fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine and, since 2011, vilazodone. In this review, the main pharmacodynamic and pharmacokinetic properties of the six commercially available SSRIs are described, focusing on side and toxic effects, chemical-clinical correlations, interactions with other drugs, the role of therapeutic drug monitoring (TDM) and related bioanalytical methodologies.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors

    Mandrioli R, Mercolini L, Saracino MA, Raggi MA

    Source

    Current medicinal chemistry 19:12 2012 pg 1846-63

    MeSH

    Benzofurans
    Citalopram
    Depressive Disorder
    Drug Monitoring
    Fluoxetine
    Fluvoxamine
    Humans
    Indoles
    Paroxetine
    Piperazines
    Serotonin Uptake Inhibitors
    Sertraline

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    22414078